Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica

Table 1

Clinical features of NMO patients.

Patient number	Age (yrs)	Disease duration (yrs)	Follow-up duration (mo)	EDSS	Immunosuppressive treatment
1	54	4	31	0	AZT
2	19	2	37	2.5	AZT
3	38	6	53	1.5	MMF
4	61	1	35	2	None
5	19	1	30	3	AZT
6	63	12	14	8	MTX then AZT
7	27	3	6	3.5	RTX
8	46	0.1	2.5	4	CYC
9	62	1.5	0.5	5.5	PE
10	54	1	6	3.5	AZT
Mean ± SD	44.3 ± 17.5	3.2 ± 3.8	26.5 ± 16	3.4 ± 3

yrs: years; mo: months; disease duration: duration from the first symptom of the disease to the first blood draw; follow-up duration: duration from the first to the last blood draw; EDSS: EDSS score evaluating disease severity; AZT: azathioprine; MMF: mycophenolate mofetil; RTX: rituximab; MTX: mitoxantrone; CYC: cyclophosphamide; PE: plasma exchanges.